CClinicalTrials.gg
Enrolling by invitationNCT01517425iPSCUpdated Jan 16, 2025

Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells

An observational study in Coronary Artery Disease, sponsored by Scripps Translational Science Institute. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Scripps Translational Science Institute · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

This research is being done to understand how changes in DNA may put people at risk for developing coronary artery disease. Stem cells will be made using cells from blood and/or skin biopsy samples. We are trying to understand which specific changes in DNA negatively impact a person's health.

02

Conditions studied

  • Coronary Artery Disease
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects previously enrolled in the Scripps Genebank or Healthy Elderly Active Longevity (HEAL) Cohort

Inclusion criteria

Cases:

  1. Previously enrolled in the CAD module of the Genebank at Scripps Clinic Registry
  2. Eligible to have their blood drawn
  3. Be reliable, cooperative and willing to comply with all protocol-specified procedures
  4. Able to understand and grant informed consent

Controls:

  1. Previously enrolled in the Healthy Elderly Active Longevity (HEAL) Cohort
  2. Eligible to have their blood drawn
  3. Be reliable, cooperative and willing to comply with all protocol-specified procedures
  4. Able to understand and grant informed consent

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to grant informed consent.
  2. Have a significant medical condition that in the Investigator's opinion may interfere with subject's study participation.
04

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
200 participants (estimated)

Groups and cohorts

  • Cases

    Subjects previously enrolled in the Scripps Genebank Study

  • Controls

    Subjects previously enrolled in the Scripps Healthy Elderly Active Longevity (HEAL) Cohort

05

What researchers measure

Primary outcomes

  1. iPSC development

    Develop methods of iPSC generation from patients with genomic risk.

    Time frame: five years

06

Study locations

1 site
  • Scripps Translational Science Institute
    La Jolla, California 92037, United States
07

Registry details

Key details

Study ID
NCT01517425
Lead sponsor
Scripps Translational Science Institute
Responsible party
Eric Topol, MD (Director, Scripps Translational Science Institute, Scripps Translational Science Institute) — Principal investigator
First posted
Jan 25, 2012
Start date
Nov 2012
Primary completion
Jul 2025 (estimated)
Completion
Jul 2030 (estimated)
Last update
Jan 16, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion